Reverse transcriptase mutants and uses thereof
MMLV reverse transcriptase mutants with targeted amino acid substitutions address secondary structure interference and temperature-related activity issues, enhancing cDNA synthesis efficiency and thermostability for applications like PCR and prime editing.
Patent Information
- Application Number
- PCT/US2025/060916
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-27
- Filing Date
- 2025-12-22
- Publication Date
- 2026-07-02
AI Technical Summary
MMLV reverse transcriptase enzymes face challenges with secondary structure interference in RNA templates and reduced activity at elevated temperatures, leading to impaired cDNA synthesis, especially in applications requiring thermostability and reduced RNase H activity.
Development of mutant variants of MMLV reverse transcriptase with specific amino acid substitutions at key positions, enhancing thermostability and activity, allowing efficient cDNA synthesis even at elevated temperatures and reducing RNA degradation.
The mutant variants demonstrate improved activity and thermostability, enabling effective cDNA synthesis for applications such as PCR and prime editing, with reduced error rates and enhanced performance in high-temperature conditions.